Highly Active Antiretroviral Therapy and Cervical Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Positive Women
Open Access
- 20 July 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 96 (14) , 1070-1076
- https://doi.org/10.1093/jnci/djh192
Abstract
Background: Women infected with human immunodeficiency virus (HIV) have an increased risk of persistent squamous intraepithelial lesions (SILs) of the cervix. We assessed the association between use of highly active antiretroviral therapy (HAART) and regression of SIL in HIV-infected women enrolled in the Women's Interagency HIV Study, a large, multicenter, prospective cohort study. Methods: Of 2059 HIV-infected participants, 312 HIV-infected women had normal cervical cytology at baseline and were subsequently diagnosed during 7 years of follow-up with incident SIL. Pap smears, CD4+ T-cell counts, and information regarding use of HAART were obtained every 6 months. The outcome of interest was lesion regression, defined as two consecutive normal Pap smears 6 months apart. Incidence rates of SIL regression were computed among person-years at risk, both before and after HAART initiation. All statistical tests were two-sided. Results: Of 312 women, 141 had lesions that regressed to normal cytology, with a median time to regression of 2.7 years. Overall, the incidence of regression increased ( Ptrend = .002) over time after HAART was introduced. At incident SIL, median CD4+ T-cell counts were lower in women whose lesions did not regress than in women whose lesions regressed (230 versus 336 cells/ μ L; P <.01). Before HAART was introduced, the rate of lesion regression was 0.0% (95% confidence interval [CI' = 0.0% to 2.4%). After HAART was introduced, the rate was 12.5% (95% CI = 9.9% to 15.1%) and was related to post-HAART CD4+ T-cell counts ( Ptrend = .002). Conclusions: HAART use was associated with increased regression of SIL among HIV-infected women, and among women who used HAART, increased CD4+ T-cell counts were associated with a greater likelihood of regression. However, the majority of cervical lesions among HIV-infected women, even among individuals who used HAART, did not regress to normal.Keywords
This publication has 28 references indexed in Scilit:
- Effectiveness of highly active antiretroviral therapy among HIV-1 infected womenJournal of Epidemiology and Community Health, 2002
- Prevalence, Incidence, and Type‐Specific Persistence of Human Papillomavirus in Human Immunodeficiency Virus (HIV)–Positive and HIV‐Negative WomenThe Journal of Infectious Diseases, 2001
- Human Papillomavirus Infection and Associated Cervical Disease in Human Immunodeficiency Virus–Infected Women: Effect of Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2001
- Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected AdultsJNCI Journal of the National Cancer Institute, 2000
- Selection by Indication of Potent Antiretroviral Therapy Use in a Large Cohort of Women Infected with Human Immunodeficiency VirusAmerican Journal of Epidemiology, 2000
- Type-Specific Persistence of Human Papillomavirus DNA before the Development of Invasive Cervical CancerNew England Journal of Medicine, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Do We Still Need a Cohort Study of Women with HIV Infection?Epidemiology, 1998
- Human Papillomavirus Infection in Women Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997